A Protective Measles Virus-derived Vaccine Inducing Long-lasting Immune Responses Against Influenza A Virus H7N9

Overview

Journal NPJ Vaccines

Date 2023 Mar 25

PMID 36964176

Authors

Cindy Horner

Anna H Fiedler

Bianca S Bodmer

Lisa Walz

Vivian A Scheuplein

Stefan Hutzler

Mikhail N Matrosovich

Veronika von Messling

Michael D Muhlebach

Affiliations

Soon will be listed here.

Abstract

A novel Influenza A virus (subtype H7N9) emerged in spring 2013 and caused considerable mortality in zoonotically infected patients. To be prepared for potential pandemics, broadly effective and safe vaccines are crucial. Recombinant measles virus (MeV) encoding antigens of foreign pathogens constitutes a promising vector platform to generate novel vaccines. To characterize the efficacy of H7N9 antigens in a prototypic vaccine platform technology, we generated MeVs encoding either neuraminidase (N9) or hemagglutinin (H7). Moraten vaccine strain-derived vaccine candidates were rescued; they replicated with efficiency comparable to that of the measles vaccine, robustly expressed H7 and N9, and were genetically stable over 10 passages. Immunization of MeV-susceptible mice triggered the production of antibodies against H7 and N9, including hemagglutination-inhibiting and neutralizing antibodies induced by MV-H7(P) and neuraminidase-inhibiting antibodies by MV-N9(P). Vaccinated mice also developed long-lasting H7- and N9-specific T cells. Both MV-H7(P) and MV-N9(P)-vaccinated mice were protected from lethal H7N9 challenge.

References

Couzens L, Gao J, Westgeest K, Sandbulte M, Lugovtsev V, Fouchier R . An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera. J Virol Methods. 2014; 210:7-14. DOI: 10.1016/j.jviromet.2014.09.003. View

Schwartzman L, Cathcart A, Pujanauski L, Qi L, Kash J, Taubenberger J . An Intranasal Virus-Like Particle Vaccine Broadly Protects Mice from Multiple Subtypes of Influenza A Virus. mBio. 2015; 6(4):e01044. PMC: 4513078. DOI: 10.1128/mBio.01044-15. View

Radecke F, Spielhofer P, Schneider H, Kaelin K, Huber M, Dotsch C . Rescue of measles viruses from cloned DNA. EMBO J. 1995; 14(23):5773-84. PMC: 394696. DOI: 10.1002/j.1460-2075.1995.tb00266.x. View

Carter D, Bloom C, Kirchenbaum G, Tsvetnitsky V, Isakova-Sivak I, Rudenko L . Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine. Vaccine. 2014; 33(1):108-16. DOI: 10.1016/j.vaccine.2014.11.008. View

Bender B, Croghan T, Zhang L, Small Jr P . Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J Exp Med. 1992; 175(4):1143-5. PMC: 2119177. DOI: 10.1084/jem.175.4.1143. View

McMichael A, Gotch F, Noble G, Beare P . Cytotoxic T-cell immunity to influenza. N Engl J Med. 1983; 309(1):13-7. DOI: 10.1056/NEJM198307073090103. View

Genzel Y, Reichl U . Continuous cell lines as a production system for influenza vaccines. Expert Rev Vaccines. 2009; 8(12):1681-92. DOI: 10.1586/erv.09.128. View

Horner C, Schurmann C, Auste A, Ebenig A, Muraleedharan S, Dinnon 3rd K . A highly immunogenic and effective measles virus-based Th1-biased COVID-19 vaccine. Proc Natl Acad Sci U S A. 2020; 117(51):32657-32666. PMC: 7768780. DOI: 10.1073/pnas.2014468117. View

He X, Holmes T, Zhang C, Mahmood K, Kemble G, Lewis D . Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J Virol. 2006; 80(23):11756-66. PMC: 1642596. DOI: 10.1128/JVI.01460-06. View

10.

Ito T, Kumagai T, Yamaji Y, Sawada A, Nakayama T . Recombinant Measles AIK-C Vaccine Strain Expressing Influenza HA Protein. Vaccines (Basel). 2020; 8(2). PMC: 7349030. DOI: 10.3390/vaccines8020149. View

11.

Francis T, MAGILL T . THE ANTIBODY RESPONSE OF HUMAN SUBJECTS VACCINATED WITH THE VIRUS OF HUMAN INFLUENZA. J Exp Med. 2009; 65(2):251-9. PMC: 2133482. DOI: 10.1084/jem.65.2.251. View

12.

Lu M, Dravid P, Zhang Y, Trivedi S, Li A, Harder O . A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike. Proc Natl Acad Sci U S A. 2021; 118(12). PMC: 8000430. DOI: 10.1073/pnas.2026153118. View

13.

World Health Organization . Measles vaccines: WHO position paper, April 2017 - Recommendations. Vaccine. 2017; 37(2):219-222. DOI: 10.1016/j.vaccine.2017.07.066. View

14.

Agrati C, Gioia C, Lalle E, Cimini E, Castilletti C, Armignacco O . Association of profoundly impaired immune competence in H1N1v-infected patients with a severe or fatal clinical course. J Infect Dis. 2010; 202(5):681-9. DOI: 10.1086/655469. View

15.

Ramsauer K, Schwameis M, Firbas C, Mullner M, Putnak R, Thomas S . Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial. Lancet Infect Dis. 2015; 15(5):519-27. DOI: 10.1016/S1473-3099(15)70043-5. View

16.

Walz L, Kays S, Zimmer G, von Messling V . Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype. J Virol. 2018; 92(17). PMC: 6096819. DOI: 10.1128/JVI.01006-18. View

17.

Shen Z, Reznikoff G, Dranoff G, Rock K . Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol. 1997; 158(6):2723-30. View

18.

Hewett J, Tannous B, Niland B, Nery F, Zeng J, Li Y . Mutant torsinA interferes with protein processing through the secretory pathway in DYT1 dystonia cells. Proc Natl Acad Sci U S A. 2007; 104(17):7271-6. PMC: 1855419. DOI: 10.1073/pnas.0701185104. View

19.

Belser J, Gustin K, Pearce M, Maines T, Zeng H, Pappas C . Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature. 2013; 501(7468):556-9. PMC: 7094885. DOI: 10.1038/nature12391. View

20.

Kreijtz J, Wiersma L, de Gruyter H, Vogelzang-van Trierum S, van Amerongen G, Stittelaar K . A single immunization with modified vaccinia virus Ankara-based influenza virus H7 vaccine affords protection in the influenza A(H7N9) pneumonia ferret model. J Infect Dis. 2014; 211(5):791-800. PMC: 4402375. DOI: 10.1093/infdis/jiu528. View